Search Within

Clifford Hudis

Formats
  1. Journal Article (483)
  2. Meeting Abstract (393)
  3. Book Section (15)
  4. Conference Paper (10)
  5. Book Whole (2)
  6. Guidelines (1)
  7. Review (1)
Groups
  1. Breast Medicine Service (905)
  2. Department of Medicine (905)
  3. Solid Tumor Oncology Division (905)
  4. Survivorship Research (905)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (318)
  6. Epidemiology and Biostatistics (242)

More Groups

People
  1. Larry Norton (293)
  2. Sujata Patil (141)
  3. Andrew Seidman (116)
  4. Chau Dang (111)
  5. Maura Dickler (102)
  6. Tiffany Traina (95)

More People

Years
  1. 2025 (1)
  2. 2023 (1)
  3. 2022 (2)
  4. 2021 (4)
  5. 2020 (5)
  6. 2019 (9)

More Years

Publications
  1. Journal of Clinical Oncology (246)
  2. Cancer Research (108)
  3. Breast Cancer Research and Treatment (77)
  4. Clinical Cancer Research (33)
  5. Cancer (30)
  6. Annals of Oncology (29)

More Publications

Publishers
  1. American Society of Clinical Oncology (249)
  2. American Association for Cancer Research (163)
  3. Springer (100)
  4. Elsevier Inc. (84)
  5. Oxford University Press (55)
  6. Wiley Blackwell (45)

More Publishers

Results (905)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis
    Journal Article

    Turashvili, G.; Brogi, E.; Morrow, M.; Hudis, C.; Dickler, M.; Norton, L.; Wen, H. Y.
    Breast Cancer Research and Treatment (2017)

    Fulltext@MSK | Save
  • Axillary management of stage II/III breast cancer in patients treated with neoadjuvant systemic therapy: Results of CALGB 40601 (HER2-positive) and CALGB 40603 (triple-negative)
    Journal Article

    Ollila, D. W.; Cirrincione, C. T.; Berry, D. A.; Carey, L. A.; Sikov, W. M.; Hudis, C. A.; Winer, E. P.; Golshan, M.
    Journal of the American College of Surgeons (2017)

    Fulltext@MSK | Save
  • Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score
    Journal Article

    Mariotti, V.; Page, D. B.; Davydov, O.; Hans, D.; Hudis, C. A.; Patil, S.; Kunte, S.; Girotra, M.; Farooki, A.; Fornier, M. N.
    Journal of Bone Oncology (2017)

    Fulltext@MSK | Save
  • Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance)
    Journal Article

    Mandelblatt, J. S.; Cai, L.; Luta, G.; Kimmick, G.; Clapp, J.; Isaacs, C.; Pitcher, B.; Barry, W.; Winer, E.; Sugarman, S.; more...
    Breast Cancer Research and Treatment (2017)

    Fulltext@MSK | Save
  • Menopause is a determinant of breast aromatase expression and its associations with BMI, inflammation, and systemic markers
    Journal Article

    Brown, K. A.; Iyengar, N. M.; Zhou, X. K.; Gucalp, A.; Subbaramaiah, K.; Wang, H.; Giri, D. D.; Morrow, M.; Falcone, D. J.; Wendel, N. K.; more...
    Journal of Clinical Endocrinology and Metabolism (2017)

    Fulltext@MSK | Save
  • The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis
    Meeting Abstract

    Turashvili, G.; Brogi, E.; Morrow, M.; Wiszowaty, A.; Dickler, M.; Norton, L.; Hudis, C.; Wen, H. Y.
    Modern Pathology (2017)

    Fulltext@MSK | Save
  • Breast carcinoma with recurrence score lower than 18: Rate of locoregional recurrence in a large series with clinical follow-up
    Meeting Abstract

    Turashvili, G.; Brogi, E.; Morrow, M.; Wiszowaty, A.; Dickler, M.; Norton, L.; Hudis, C.; Wen, H. Y.
    Modern Pathology (2017)

    Fulltext@MSK | Save
  • Breast carcinoma with 21-gene recurrence score lower than 18: Rate of distant metastases in a large series with clinical follow-up
    Meeting Abstract

    Wen, H. Y.; Krystel-Whittemore, M.; Patil, S.; Pareja, F.; Bowser, Z. L.; Dickler, M.; Norton, L.; Morrow, M.; Hudis, C.; Brogi, E.
    Cancer Research (2017)

    Fulltext@MSK | Save
  • Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer
    Meeting Abstract

    Tanioka, M.; Fan, C.; Carey, L. A.; Hyslop, T.; Pitcher, B. N.; Parker, J. A.; Hoadley, K. A.; Henry, N. L.; Tolaney, S.; Dang, C.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save